Therefore, for advanced classical EGFR-mutant NSCLC, furmonertinib demonstrates a distinct advantage in terms of clinical efficacy, particularly for the 21 L858R mutation and CNS metastasis. This evidence concerns the gene EGFR and non-small cell lung carcinoma.